Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, W-135 and Y conjugate vaccine + measles, mumps, rubella and varicella vaccine (live)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Nimenrix + Priorix-Tetra refers to the concomitant administration of two separate vaccines developed by GSK. **Nimenrix** is a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) that uses tetanus toxoid as a carrier protein and is indicated for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W-135, and Y. **Priorix-Tetra** is a live attenuated vaccine containing measles, mumps, rubella, and varicella (MMRV) antigens. These biologics are typically administered together during the second year of life (12–15 months) to simplify pediatric vaccination schedules. Clinical trials have demonstrated that co-administration at different injection sites is safe and does not significantly interfere with the immunogenicity or safety profile of either vaccine, ensuring protective antibody levels against all eight targeted pathogens.
- Other names
- MenACWY-TT + MMRVMeMuRu-OKA + MenACWY-TTMMRV-Oka + MenACWY-TT
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Mumps virus antigenNeisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)TT (Tetanus toxoid)MV (Measles virus)
Beyond the preview
Go deeper on meningococcal group A, C, W-135 and Y conjugate vaccine + measles, mumps, rubella and varicella vaccine (live).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, W-135 and Y conjugate vaccine + measles, mumps, rubella and varicella vaccine (live).